Skip to main content
TipRanks
Go Ultimate75% OFF

Larimar Therapeutics (LRMR) AI Stock Analysis

1,155 Followers
LRMR

Larimar Therapeutics

(NASDAQ:LRMR)

Select Model
Rating:50Neutral
Price Target:$3.00â–¼(-0.66% Downside)
Action:reiterated
Date:11/10/26

The score is held down primarily by weak financial performance—no revenue, widening losses, and heavy cash burn that elevates financing and dilution risk. Technicals are also soft with the stock below key longer-term moving averages and negative MACD. Offsetting these factors, corporate events are constructive, highlighted by the completed rolling FDA BLA submission for nomlabofusp and strengthened leadership, which improves the near-term catalyst profile.

Positive Factors
Regulatory progressCompleting the rolling BLA submission is a material development milestone that advances nomlabofusp toward potential approval. It also provides a clearer regulatory path for the lead program, while the ongoing confirmatory Phase 3 study supports continued clinical and regulatory execution.
Negative Factors
No commercial revenueLarimar remains entirely pre-revenue, so its financial position depends on advancing clinical programs rather than recurring product sales. Until a therapy is approved and commercialized, the company lacks operating revenue to offset research, development, regulatory, and administrative expenses.

Larimar Therapeutics (LRMR) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%LRMR-10.91%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$313.73M
Dividend Yield
―
Average Volume (3M)
1.33M
Price to Earnings (P/E)
-1.5
Beta (1Y)
1.92
Revenue Growth
―
EPS Growth
-27.00%
Country
US
Employees
71
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Larimar Therapeutics Business Overview & Revenue Model

Company Description

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platf...

Larimar Therapeutics Financial Statement Overview

Summary

Pre-revenue profile with consistently large and widening losses (TTM net loss about -$173M) and accelerating cash burn (TTM operating cash flow about -$156M) are major weaknesses and increase financing/dilution risk. The main offset is low leverage with modest total debt (~$4–6M), which supports solvency flexibility, but does not eliminate the pressure from sustained negative cash flow.

Income Statement

12Very Negative

Balance Sheet

58Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-172.30M-165.32M-80.29M-36.64M-35.04M-50.31M
Net Income-172.60M-165.67M-80.60M-36.95M-35.35M-50.64M
Balance Sheet
Total Assets165.30M145.84M200.22M95.94M126.41M78.67M
Cash, Cash Equivalents and Short-Term Investments156.27M136.85M183.45M86.79M118.43M70.10M
Total Debt4.96M4.07M5.12M5.55M5.41M6.00M
Total Liabilities37.92M67.76M28.41M14.21M15.50M14.25M
Stockholders Equity127.38M78.08M171.81M81.72M110.90M64.41M
Cash Flow
Free Cash Flow-156.08M-113.29M-71.28M-33.62M-27.67M-42.44M
Operating Cash Flow-155.92M-113.20M-70.76M-33.46M-27.57M-42.10M
Investing Cash Flow55.11M100.31M-85.39M33.35M-90.96M24.17M
Financing Cash Flow172.77M65.09M161.88M30.00K75.26M19.89M

Larimar Therapeutics Technical Analysis

Technical Analysis SentimentNeutral
Last Price3.02

Price Trends

50DMA2.93Positive
100DMA3.41Negative
200DMA3.77Negative

Market Momentum

MACD-0.01Negative
RSI59.54Neutral
STOCH84.30Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRMR, the sentiment is Neutral. The current price of 3.02 is above the 20-day moving average (MA) of 2.50, above the 50-day MA of 2.93, and below the 200-day MA of 3.77, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 59.54 is Neutral, neither overbought nor oversold. The STOCH value of 84.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LRMR.

Larimar Therapeutics Risk Analysis

Larimar Therapeutics disclosed 85 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026; however, there can be no assurance that we will submit the remaining modules on our expected timeline, that the FDA will accept the BLA for filing or the FDA will approve our BLA submission for accelerated approval.Q2, 2026

Larimar Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

LRMR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LRMRLRMR50Neutral$313.73M-1.52-137.39%――-27.00%
OMEROMER48Neutral$1.27B9.16-109.40%―――
CADLCADL43Neutral$486.36M-4.19-88.58%――-171.31%
NMRANMRA43Neutral$80.59M-0.35-242.28%――21.31%
FHTXFHTX41Neutral$124.12M29.57-14.17%―357.33%―
VNDAVNDA39Underperform$241.27M-0.86-106.94%―8.11%-222.50%

* Healthcare Sector Average

Performance Comparison

0%100%LRMROMERVNDAFHTXCADLNMRADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LRMR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LRMRLarimar Therapeutics, Inc.3.02-0.51-14.45%
OMEROmeros Corporation17.498.4192.62%
VNDAVanda Pharmaceuticals3.99-0.41-9.32%
FHTXFoghorn Therapeutics, Inc.2.07-2.74-56.96%
CADLCandel Therapeutics, Inc.6.201.4731.08%
NMRANeumora Therapeutics, Inc.0.43-2.16-83.47%

Larimar Therapeutics Corporate Events

Product-Related AnnouncementsRegulatory Filings and Compliance

Larimar Therapeutics Completes Rolling FDA BLA Submission for Nomlabofusp

Positive
Nov 9, 2026

On November 9, 2026, Larimar announced completion of its rolling BLA submission to the FDA seeking accelerated approval of nomlabofusp for patients with Friedreich’s ataxia. The investigational protein replacement therapy is designed to deliver human...

Business Operations and StrategyExecutive/Board Changes

Larimar Therapeutics Appoints New President and COO

Positive
Sep 29, 2026

On September 29, 2026, Larimar Therapeutics appointed John B. Harlow Jr. as president and chief operating officer under an employment agreement that includes a $560,000 base salary, performance-based bonus eligibility, and standard executive severanc...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026